Molecular Partners (NASDAQ:MOLN) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Molecular Partners (NASDAQ:MOLN) posted its quarterly earnings data on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03), Zacks reports.

Molecular Partners Trading Down 10.4%

Molecular Partners stock opened at $4.22 on Friday. Molecular Partners has a 12-month low of $3.36 and a 12-month high of $5.36. The firm has a market capitalization of $170.40 million, a price-to-earnings ratio of -2.12 and a beta of 1.03. The firm has a 50 day moving average of $4.54 and a 200 day moving average of $4.17.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on MOLN. HC Wainwright initiated coverage on shares of Molecular Partners in a research report on Tuesday, January 27th. They issued a “buy” rating and a $13.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. Finally, JPMorgan Chase & Co. reduced their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research note on Monday, December 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.